Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|August 14, 2012
Handling of missing data in long-term clinical trials: a case studyMark Janssens, Geert Molenberghs, René Kerstens
The American Journal of Gastroenterology|April 16, 2014
Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysisAnton Emmanuel, Marina Cools, Lieve Vandeplassche, et al.
The New England Journal of Medicine|May 30, 2008
A placebo-controlled trial of prucalopride for severe chronic constipationMichael Camilleri, René Kerstens, An Rykx, et al.
Digestion|May 14, 2003
Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trialGeorges Coremans, René Kerstens, Martine De Pauw, et al.
The American Journal of Gastroenterology|September 29, 2021
Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal BloatingKyle Staller, Jimmy Hinson, René Kerstens, et al.
United European Gastroenterology Journal|June 12, 2014
Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysisJan Tack, Eamonn Quigley, Michael Camilleri, et al.
Drug Design, Development and Therapy|December 28, 2012
Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I studyWilliam B Smith, Erik Mannaert, Tom Verhaeghe, et al.
Gastroenterology|September 21, 2014
Prucalopride is no more effective than placebo for children with functional constipationSuzanne M Mugie, Bartosz Korczowski, Piroska Bodi, et al.
Digestive Diseases and Sciences|April 9, 2016
Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical TrialsMichael Camilleri, Hubert Piessevaux, Yan Yiannakou, et al.
Blood|February 1, 2007
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndromePierre Fenaux, Azra Raza, Ghulam J Mufti, et al.
Pageof 2